Skip to main content
×
Home
    • Aa
    • Aa

Evidence-based pharmacotherapy for personality disorders

  • Luis H. Ripoll (a1), Joseph Triebwasser (a1) and Larry J. Siever (a1)
Abstract
Abstract

Patients with personality disorders are prescribed psychotropic medications with greater frequency than almost any other diagnostic group. Prescribing practices in these populations are often based on anecdotal evidence rather than rigorous data. Although evidence-based psychotherapy remains an integral part of treatment, Axis II psychopathology is increasingly conceptualized according to neurobiological substrates that correspond to specific psychopharmacological strategies. We summarize the best available evidence regarding medication treatment of personality disordered patients and provide optimal strategies for evidence-based practice. Most available evidence is concentrated around borderline and schizotypal personality disorders, with some additional evidence concerning the treatment of avoidant and antisocial personality disorders. Although maladaptive personality symptoms respond to antidepressants, antipsychotics, mood stabilizers, and other medications, evidence-based pharmacotherapy is most useful in treating circumscribed symptom domains and induces only partial improvement. Most available evidence supports use of medication in reducing impulsivity and aggression, characteristic of borderline and antisocial psychopathology. Efforts have also begun to reduce psychotic-like symptoms and improve cognitive deficits characteristic of schizotypy. Indirect evidence is also provided for psychopharmacological reduction of social anxiety central to avoidant personality disorder. Evidence-based practice requires attention to domains of expected clinical improvement associated with a medication, relative to the potential risks. The development of future rational pharmacotherapy will require increased understanding of the neurobiological underpinnings of personality disorders and their component dimensions. Increasing efforts to translate personality theory and social cognitive neuroscience into increasingly specific neurobiological substrates may provide more effective targets for pharmacotherapy.

Copyright
Corresponding author
Address for correspondence: L. H. Ripoll, M.D., Mental Illness Research Education and Clinical Center, James J. Peters VA Medical Center, 130 W. Kingsbridge Rd., Bronx, NY 10468. Tel.: 718-584-9000 (ext. 5225)Fax: 718-364-3576Email: Luis.Ripoll@mssm.edu
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

PF Abraham , JR Calabrese (2008). Evidence-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of Affective Disorders 111, 2130.

HS Akiskal (2004). Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatrica Scandinavica 110, 401407.

LE Alden , JM Paosa , CT Taylor , AG Ryder (2002). Avoidant personality disorder: current status and future directions. Journal of Personality Disorders 16, 129.

AP Aldenkamp , J Arends , HPR Boorsma , L Diepman , (2002). Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 43, 1926.

C Allgulander (1999). Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatrica Scandinavica 100, 193198.

C Allgulander , R Mangano , J Zhang , AA Dahl , (2004). Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharmacology 19, 387396.

APA (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry 158 (October supplement), 152.

D Baldwin , J Bobes , DJ Stein , I Scharwachter , (1999). Paroxetine in social phobia/social anxiety disorder. Randomised double-blind, placebo-controlled study. Paroxetine Study. British Journal of Psychiatry 175, 120126.

ES Barratt , TA Kent , SG Bryant , AR Felthous (1991). A controlled trial of phenytoin in impulsive aggression. Journal of Clinical Psychopharmacology 11, 388389.

ES Barratt , MS Stanford , AR Felthous , TA Kent (1997). The effects of phenytoin on impulsive and pre-meditated aggression: a controlled study. Journal of Clinical Psychopharmacology 17, 341349.

J Battaglia , TK Wolff , DS Wagner-Johnson , AJ Rush , (1999). Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. International Clinical Psychopharmacology 14, 361372.

DS Bender , AE Skodol (2007). Borderline personality as a self-other representational disturbance. Journal of Personality Disorders 21, 500517.

H Bergida , MF Lenzenweger (2006). Schizotypy and sustained attention: confirming evidence from an adult community sample. Journal of Abnormal Psychology 115, 545551.

RJR Blair (2005). Responding to the emotions of others: dissociating forms of empathy through the study of typical and psychiatric populations. Consciousness and Cognition 14, 698718.

S Blomhoff , TT Haug , K Hellstrom , I Holme , (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry 179, 2330.

MP Bogenschutz , PH Nurnberg (2004). Olanzapine vs. placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 65, 104109.

MJ Bohus , GB Landwehrmeyer , CE Stiglmayr , MF Limberger , (1999). Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. Journal of Clinical Psychiatry 60, 598603.

P Brambilla , PH Soloff , M Sala , MA Nicoletti , (2004). Anatomical MRI study of borderline personality disorder patients. Psychiatry Research 131, 125133.

EF Coccaro , RJ Kavoussi (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry 54, 10811088.

EF Coccaro , RJ Kavoussi , RL Hauger (1995). Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. International Clinical Psychopharmacology 10, 177179.

EF Coccaro , RJ Lee , RJ Kavoussi (2009). A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. Journal of Clinical Psychiatry 70, 653662.

EF Coccaro , LJ Siever , HM Klar , G Maurer , (1989). Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry 46, 587599.

RW Cowdry , DL Gardner (1988). Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry 45, 111119.

J Davidson , J Yaryura-Tobias , R DuPont , L Stallings , (2004 b). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 118125.

JR Davidson , EB Foa , JD Huppert , FJ Keefe , (2004 a). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 61, 10051013.

JM de la Fuente , F Lotstra (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology 4, 479486.

RA Depue , JV Morrone-Strupinsky (2005). A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation. Behavioral and Brain Sciences 28, 313395.

L Ekselius , L von Knorring (1998). Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. International Clinical Psychopharmacology 13, 205211.

J Evenden (1999). Impulsivity: a discussion of clinical and experimental findings. Journal of Psychopharmacology 13, 180192.

P Fonagy , P Luyten (2009). A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder. Development and Psychopathology 21, 13551381.

FR Frankenburg , MC Zanarini (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry 63, 442446.

FR Frankenburg , MC Zanarini (2006). Obesity and obesity-related illnesses in borderline patients. Journal of Personality Disorders 20, 7180.

DL Gardner , RW Cowdry (1986 a). Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology 6, 236239.

DL Gardner , RW Cowdry (1986 b). Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. American Journal of Psychiatry 143, 519522.

SC Goldberg , SC Schulz , PM Schulz , RJ Resnick , (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo. Archives of General Psychiatry 43, 680686.

M Goodman , A New , L Siever (2004). Trauma, genes, and the neurobiology of personality disorders. Annals of the New York Academy of Sciences 1032, 104116.

GM Goodwin , CL Bowden , JR Calabrese , H Grunze , (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry 65, 432441.

H Griengl , A Sendera , K Dantendorfer (2001). Naltrexone as a treatment of self-injurious behavior – a case report. Acta Psychiatrica Scandinavica 103, 234236.

T Hamazaki , S Sawazaki , M Itomura , E Asaoka , (1996). The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. Journal of Clinical Investigation 97, 11291133.

T Hamazaki , A Thienprasert , K Kheovichai , S Samuhaseneetoo , (2002). The effect of docosahexaenoic acid on aggression in elderly Thai subjects – a placebo-controlled double-blind study. Nutritional Neuroscience 5, 3741.

RG Heimberg , MR Liebowitz , DA Hope , FR Schneier , (1998). Cognitive behavioral group therapy vs. phenelzine therapy for social phobia: 12-week outcome. Archives of General Psychiatry 55, 11331141.

C Henry , V Mitropoulou , AS New , HW Koenigsberg , (2001). Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences. Journal of Psychiatric Research 35, 307312.

SC Herpertz , M Zanarini , CS Schulz , L Siever , (2007). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. World Journal of Biological Psychiatry 8, 212244.

GA Higgins , M Enderlin , M Haman , PJ Fletcher (2003). The 5-HT2A receptor antagonist M100,907 attenuates motor and ‘impulsive-type’ behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berlin) 170, 309319.

E Hollander , A Allen , RP Lopez , CA Bienstock , (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry 62, 199203.

E Hollander , AC Swann , EF Coccaro , P Jiang , (2005). Impact of trait impulsivity and state aggression on divalproex vs. placebo response in borderline personality disorder. American Journal of Psychiatry 162, 621624.

RJ Houston , LO Bauer , VM Hesselbrock (2004). Effects of borderline personality disorder features and a family history of alcohol or drug dependence on P300 in adolescents. International Journal of Psychophysiology 53, 5770.

N Huband , M Ferriter , R Nathan , H Jones (2010). Antiepileptics for aggression and associated impulsivity. Cochrane Database for Systematic Reviews. Issue 2, Art. No. CD003499.

IMCTGMSP, H Katschnig (1997). The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience 247, 7180.

T Ingenhoven , P Lafay , T Rinne , J Passchier , (2010). Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. Journal of Clinical Psychiatry 71, 1425.

HV Jensen , J Andersen (1989). An open, noncomparative study of amoxapine in borderline disorders. Acta Psychiatrica Scandinavica 79, 8993.

FD Juengling , C Schmahl , B Hesslinger , D Ebert , (2003). Positron emission tomography in female patients with borderline personality disorder. Journal of Psychiatric Research 37, 109115.

S Kasper , DJ Stein , H Loft , R Nil (2005). Escitalogram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. British Journal of Psychiatry 186, 222226.

P Keck , A Buffenstein , J Ferguson , J Feighner , (1998). Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140, 173184.

HW Koenigsberg , D Reynolds , M Goodman , AS New , (2003). Risperidone in the treatment of schizotypal personality disorder. Journal of Clinical Psychiatry 64, 628634.

M Lader , K Stender , V Burger , R Nil (2004). Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety 19, 241248.

R Langdon , M Coltheart (2004). Recognition of metaphor and irony in young adults: the impact of schizotypal personality traits. Psychiatry Research 125, 920.

P Leiberich , MK Nickel , K Tritt , F Pedrosa Gil (2008). Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up. Journal of Psychopharmacology 22, 805808.

U Lepola , B Bergtholdt , J St Lambert , KL Davy , (2004). Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry 65, 222229.

JJ Levitt , CF Westin , PG Nestor , RS Estepar , (2004). Shape of caudate nucleus and its cognitive correlates in neuroleptic-naïve schizotypal personality disorder. Biological Psychiatry 55, 177184.

K Lieb , B Vollm , G Rucker , A Timmer , (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomized trials. British Journal of Psychiatry 196, 412.

K Lieb , MC Zanarini , C Schmahl , MM Linehan , (2004). Borderline personality disorder. Lancet 364, 453461.

MR Liebowitz , AJ Gelenberg , D Munjack (2005 a). Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 62, 190198.

MR Liebowitz , RG Heimberg , FR Schneier , DA Hope , (1999). Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression and Anxiety 10, 8998.

MR Liebowitz , DF Klein (1981). Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatric Clinics of North America 4, 6787.

MR Liebowitz , RM Mangano , J Bradwejn , G Asnis , (2005 b). A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 238247.

MR Liebowitz , MB Stein , M Tancer , D Carpenter , (2002). A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 63, 6674.

PS Links , M Steiner , I Boiago , D Irwin (1990). Lithium therapy for borderline patients: preliminary findings. Journal of Personality Disorders 4, 173181.

TH Loew , MK Nickel (2008). Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up. Journal of Clinical Psychopharmacology 28, 355357.

TH Loew , MK Nickel , M Muehlbacher , P Kaplan , (2006). Topiramate treatment of women with borderline personality disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 26, 6166.

AW Loranger , N Sartorius , A Andreoli , P Berger , (1994). The international personality disorders examination. The world health organization/alcohol, drug abuse, and mental health administration international pilot study of personality disorders. Archives of General Psychiatry 51, 215224.

M Lott , JH Greist , JW Jefferson , KA Kobak , (1997). Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. Journal of Clinical Psychophamacology 17, 255260.

KM Malone , EM Corbitt , S Li , JJ Mann (1996). Prolactin response to fenfluramine and suicide attempt lethality in major depression. British Journal of Psychiatry 168, 324329.

JA Mattes (2005). Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 25, 575579.

JA Mattes (2008). Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 310315.

J Mauchnik , C Schmahl (2010). The latest neuroimaging findings in borderline personality disorder. Current Psychiatry Reports 12, 4655.

MM McClure , DM Barch , MJ Romero , MJ Minzenberg , (2007 b). The effects of guanfacine on context-processing abnormalities in schizotypal personality disorder. Biological Psychiatry 61, 11571160.

MM McClure , PD Harvey , M Goodman , J Triebwasser , (2010). Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 35, 13561362.

MM McClure , MJ Romero , CR Bowie , A Reichenberg , (2007 a). Visual-spatial learning and memory in schizotypal personality disorder: continued evidence for the importance of working memory in the schizophrenia spectrum. Archives of Clinical Neuropsychology 22, 109116.

MD McGee (1997). Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry 58, 3233.

PT Mehlman , JD Higley , I Faucher , AA Lilly , (1994). Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates. American Journal of Psychiatry 151, 14851491.

D Mercer , AB Douglass , PS Links (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. Journal of Personality Disorders 23, 156174.

SA Montgomery , D Montgomery (1982). Pharmacological prevention of suicidal behavior. Journal of Affective Disorders 4, 291298.

SA Montgomery , R Nil , N Durr-Pal , H Loft , (2005). A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 12701278.

SA Montgomery , D Roy , DB Montgomery (1983). The prevention of recurrent suicidal acts. British Journal of Clinical Pharmacology 15, 183S188S.

AS New , EA Hazlett , MS Buchsbaum , M Goodman , (2002). Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Archives of General Psychiatry 59, 621629.

AS New , R Trestman , V Mitropoulou , DS Benishay , (1997). Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Research 69, 1726.

AS New , R Trestman , V Mitropoulou , M Goodman , (2004). Low prolactin response to fenfluramine in impulsive aggression. Journal of Psychiatric Research 38, 223230.

MK Nickel , TH Loew (2008). Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. European Psychiatry 23, 115117.

MK Nickel , TH Loew , F Pedrosa Gil (2007). Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology 191, 10231026.

MK Nickel , M Muehlbacher , C Nickel , C Kettler , (2006). Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 163, 833838.

MK Nickel , C Nickel , P Kaplan , C Lahmann , (2005). Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biological Psychiatry 57, 495499.

MK Nickel , C Nickel , FO Mitterlehner , K Tritt , (2004). Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 65, 15151519.

R Noyes , G Moroz , JR Davidson , MR Liebowitz , (1997). Moclobemide in social phobia: a controlled dose-response trial. Journal of Clinical Psychopharmacology 17, 247254.

MA Oquendo , A Krunic , RV Parsey , M Milak , (2005). Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder. Neuropsychopharmacology 30, 11631172.

AC Pande , JR Davidson , JW Jefferson , CA Janney , (1999). Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of Clinical Psychopharmacology 19, 341348.

AC Pande , DE Feltner , JW Jefferson , JR Davidson , (2004). Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. Journal of Clinical Psychopharmacology 24, 141149.

J Paris (2004). Borderline or bipolar? Distinguishing borderline personality disorder from bipolar spectrum disorders. Harvard Review of Psychiatry 12, 140145.

J Paris (2005). Borderline personality disorder. Canadian Medical Association Journal 172, 15791583.

B Parsons , FM Quitkin , PJ McGrath , JW Stewart , (1989). Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacological Bulletin 25, 524534.

JC Pascual , S Oller , J Soler , J Barrachina , (2004). Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. Journal of Clinical Psychiatry 65, 12811283.

JC Pascual , M Madre , J Soler , J Barrachina , (2006). Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 39, 117118.

JC Pascual , J Soler , D Puigdemont , R Perez-Egea , (2008). Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. Journal of Clinical Psychiatry 69, 603608.

M Peet , C Stokes (2005). Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 65, 10511059.

A Philipsen , H Richter , C Schmahl , J Peters , (2004 a). Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry 65, 14141419.

A Philipsen , C Schmahl , K Lieb (2004 b). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 37, 196199.

GJ Pickup (2006). Theory of mind and its relation to schizotypy. Cognitive Neuropsychiatry 11, 177192.

W Pitchot , M Hansenne , E Pinto , J Reggers , (2005). 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biological Psychiatry 58, 854858.

GP Placidi , MA Oquendo , KM Malone , YY Huang , (2001). Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biological Psychiatry 50, 783791.

MI Posner , MK Rothbart , N Vizueta , KN Levy , (2002). Attentional mechanisms of borderline personality disorder. Proceedings of the National Academy of Sciences USA 99, 1636616370.

AR Prossin , TM Love , RA Koeppe , JK Zubieta , (2010). Dysregulation of regional endogenous opioid function in borderline personality disorder. American Journal of Psychiatry 167, 925933.

DB Reich , MC Zanarini , KA Bieri (2009). A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology 24, 270275.

J Reich (2002). Drug treatment of personality disorder traits. Psychiatric Annals 32, 590596.

K Rickels , R Mangano , A Khan (2004). A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 488496.

A Rifkin , F Quitkin , C Carrillo , AG Blumberg , (1972). Lithium carbonate in emotionally unstable character disorder. Archives of General Psychiatry 27, 519523.

T Rinne , W van den Brink , L Wouters , R van Dyck (2002). SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry 159, 20482054.

N Rusch , LT van Elst , P Ludaescher , M Wilke , (2003). A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage 20, 385392.

MJ Russ , SS Campbell , T Kakuma , K Harrison , (1991). EEG theta activity and pain insensitivity in self-injurious borderline patients. Psychiatry Research 89, 201214.

C Salzman , AN Wolfson , A Schatzberg , J Looper , (1995). Effects of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology 15, 2329.

M Samuelsson , J Jokinen , AL Nordstrom , P Nordstrom (2006). CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatrica Scandinavica 113, 4447.

JR Saper (2000). Borderline personality, opioids, and naltrexone. Headache 40, 765766.

FR Schneier , D Gortz , R Campeas , B Fallon , (1998). Placebo-controlled trial of moclobemide in social phobia. British Journal of Psychiatry 172, 7077.

SC Schulz , MC Zanarini , A Bateman , M Bohus , (2008). Olanzapine for the treatment of borderline personality disorder: variable-dose 12-week randomized double-blind placebo-controlled study. British Journal of Psychiatry 193, 485492.

SS Shafti , B Shahveisi (2010). Olanzapine vs. haloperidol in the management of borderline personality disorder: a randomized double-blind trial. Journal of Clinical Psychopharmacology 30, 4447.

MH Sheard (1971). Effect of lithium on human aggression. Nature 230, 113114.

LJ Siever , MS Buchsbaum , AS New , J Spiegel-Cohen , (1999). D,L-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 20, 413423.

LJ Siever , KL Davis (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry 148, 16471658.

LJ Siever , KL Davis (2004). The pathophysiology of schizophrenia disorders: perspectives from the spectrum. American Journal of Psychiatry 161, 398413.

D Simeon , B Stanley , A Frances , JJ Mann , (1992). Self-mutilation in personality disorders: psychological and biological correlates. American Journal of Psychiatry 149, 221226.

EB Simpson , S Yen , E Costello , K Rosen , (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 65, 379385.

AE Skodol , JG Gunderson , MT Shea , TH McGlashan , (2005). The collaborative longitudinal personality disorders study (CLPS): overview and implications. Journal of Personality Disorders 19, 487504.

DJ Smith , WJ Muir , DH Blackwood (2004). Is borderline personality disorder part of the bipolar spectrum? Harvard Review of Psychiatry 12, 133139.

H Soderstrom , A Foresman (2004). Elevated triiodothyronine in psychopathy – possible physiological mechanisms. Journal of Neural Transmission 111, 739744.

J Soler , JC Pascual , J Campins , J Barrachina , (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry 162, 12211224.

PH Soloff , J Cornelius , A George , S Nathan , (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry 50, 377385.

PH Soloff , A George , RS Nathan , PM Schulz , (1986 a). Paradoxical effects of amitryptiline on borderline patients. American Journal of Psychiatry 143, 16031605.

PH Soloff , A George , RS Nathan , PM Schulz , (1986 b). Amitryptiline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacology Bulletin 22, 177182.

PH Soloff , A George , RS Nathan , PM Schulz , (1986 c). Progress in pharmacotherapy of borderline disorders. Archives of General Psychiatry 43, 691697.

PH Soloff , A George , RS Nathan , PM Schulz , (1987). Behavioral dyscontrol in borderline patients treated with amitryptiline. Psychopharmacology Bulletin 23, 177181.

PH Soloff , A George , RS Nathan , PM Schulz , (1989). Amitryptiline vs. haloperidol in borderlines: final outcomes and predictors of response. Journal of Clinical Psychopharmacology 9, 238246.

SM Southwick , JD Bremner , A Rasmusson , CA Morgan , (1999). Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biological Psychiatry 46, 11921204.

B Stanley , LJ Siever (2010). The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. American Journal of Psychiatry 167, 2439.

DJ Stein , M Versiani , T Hair , R Kumar (2002). Efficacy of paroxetine for relapse prevention in social anxiety disorder. Archives of General Psychiatry 59, 11111118.

MB Stein , AJ Fyer , JR Davidson , MH Pollack , (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. American Journal of Psychiatry 156, 756760.

MB Stein , MR Liebowitz , RB Lydiard , CD Pitts , (1998). Paroxetine treatment of gereralized social phobia (social anxiety disorder): a randomized controlled trial. Journal of the American Medical Association 280, 708713.

MB Stein , MH Pollack , A Bystritsky , JE Kelsey , (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmalogy 177, 280288.

JR Strawn , TD Geracioti (2008). Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depression and Anxiety 25, 260271.

R Tandon (2000). Introduction: ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics. British Journal of Clinical Pharmacology 49(Suppl. 1), 1S3S.

NJ Thurauf , HA Washeim (2000). The effects of exogenous analgesia in a patient with borderline personality disorder (BPD) and severe self-injurious behavior. European Journal of Pain 4, 107109.

L Traskman , M Asberg , L Bertilsson , L Sjostrand (1981). Monoamine metabolites in CSF and suicidal behavior. Archives of General Psychiatry 38, 631636.

K Tritt , C Nickel , C Lahmann , PK Leiberich , (2005). Lamotrigine treatment of aggression in female borderline patients: a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology 19, 287291.

M van Ameringen , J Oakman , C Mancini , B Pipe , (2004). Predictors of response in generalized social phobia: effect of age of onset. Journal of Clinical Psychopharmacology 24, 4248.

MA van Ameringen , RM Lane , JR Walker , RC Bowen , (2001). Sertraline treatment of generalized social phobia: a 20-week, doubleblind, placebo-controlled study. American Journal of Psychiatry 158, 275281.

IM van Vliet , JA den Boer , HG Westenberg (1994). Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berlin) 115, 128134.

RJ Verkes , RC van der Mast , MW Hengeveld , JP Tuyl , (1998). Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry 155, 543547.

M Versiani , AE Nardi , FD Mundim , AB Alves , (1992). Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry 161, 353360.

M Virkkunen , R Rawlings , R Tokola , RE Poland , (1994). CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Archives of General Psychiatry 51, 2027.

SS Welch , MM Linehan (2002). High-risk situations associated with parasuicide and drug use in borderline personality disorder. Journal of Personality Disorders 16, 561569.

KD Wilner , RJ Anziano , AC Johnson , JJ Miceli , (2002). The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. Journal of Clinical Psychopharmacology 22, 206210.

CA Winstanley , DE Theobald , JW Dalley , JC Glennon , (2004). 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity. Interactions with global 5-HT depletion. Psychopharmacology (Berlin) 176, 376385.

MC Zanarini , FR Frankenburg (2001). Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry 62, 849854.

MC Zanarini , FR Frankenburg (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. American Journal of Psychiatry 160, 167169.

MC Zanarini , FR Frankenburg , J Hennen , DB Reich , (2004 a). Axis I comorbidity of borderline personality disorder: Description of six-year course and prediction to time-to-remission. American Journal of Psychiatry 161, 21082114.

MC Zanarini , FR Frankenburg , AA Vujanovic , J Hennen , (2004 c). Axis II comorbidity of borderline personality disorder: Description of six-year course and prediction to time-to-remission. Acta Psychiatrica Scandinavica 110, 416420.

AA Ziegenhorn , S Roepke , NC Schommer , A Merkl , (2009). Clonidine improves hyperarousal in borderline personality disorder with or without comorbid post-traumatic stress disorder: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 29, 170173.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: